Clinical Decision Trees to Guide Physical Therapy Management of Persons with Huntington's Disease

Nora E Fritz1, Deb A Kegelmeyer2, Ashwini K Rao3

  • 1Departments of Health Care Sciences and Neurology, Wayne State University, Detroit, MI, USA.

Insights

Physical therapists can now use new guideline-based algorithms and a core set of assessments to improve care for individuals with Huntington's disease (HD). Strategies are also provided to overcome barriers to implementing these physical therapy clinical practice guidelines (CPG).

Area of Science:

  • Neurology
  • Physical Therapy
  • Clinical Practice Guidelines

Background:

  • Published physical therapy clinical practice guidelines (CPG) for Huntington's disease (HD) in 2020.
  • Recommendations were categorized by six primary movement impairment classifications.

Purpose of the Study:

  • To facilitate the implementation of the 2020 physical therapy CPG for HD.
  • Developed guideline-based algorithms for assessments and interventions.
  • Provided strategies to overcome barriers to CPG implementation.

Main Methods:

  • Conducted a literature review of 26 papers on physical therapy interventions in HD.
  • Identified assessments for primary movement impairments and searched for 28 papers on their clinometric/psychometric properties in HD.
  • Evaluated assessments using modified Movement Disorder Society criteria.

Main Results:

  • Identified a core set of physical therapy assessments for HD: Six Minute Walk Test, Timed Up and Go Test, Berg Balance Scale, and SF-36.
  • Developed guideline-based decision trees for implementing CPG across the care continuum.
  • Proposed strategies for overcoming implementation barriers, including training and caregiver engagement.

Conclusions:

  • Knowledge translation documents are crucial for promoting the adoption of physical therapy CPGs into clinical practice.
  • The developed algorithms, assessments, and strategies aim to enhance the practical application of HD physical therapy guidelines.
Abstract

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
354
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
672
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
23
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
24
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
248
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
28